Notice of Proposed Sale · 144
MannKind Corporation
MNKDNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- MannKind Corporation
- Issuer CIK
- 0000899460
- SEC file number
- 000-50865
- Phone
- 8186615000
- Person for whose account securities are to be sold
- DAVID THOMSON
- Relationships to issuer
- Officer
- Street
- 1 Casper Street
- City
- Danbury
- State / country code
- CT
- Postal code
- 06810
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 24,109 | 97,400.36 | 308,950,166 | 07/17/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/15/2026 | Restricted Stock Units | Issuer | 11,462 | N | 07/15/2026 | N/A |
| Common | 07/15/2026 | Performance Stock Units | Issuer | 12,647 | N | 07/15/2026 | N/A |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| 10b5-1 Sales for DAVID THOMSON | Common | 05/12/2026 | 3,033 | 9,984.03 |
Seller — prior-sale row 1, entry 1
- Name
- 10b5-1 Sales for DAVID THOMSON
- Street
- 1 Casper Street
- City
- Danbury
- State / country code
- CT
- Postal code
- 06810
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 07/17/2026
- Signed
- /s/ David Thomson
- Plan adoption dates
- 08/27/2025
Company context
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.